CP-673451: A Selective ATP-Competitive PDGFR Tyrosine Kinase Inhibitor for Cancer Research

Executive Summary: CP-673451 is a highly selective ATP-competitive inhibitor targeting PDGFRα and PDGFRβ with nanomolar potency (IC₅₀ = 10 nM and 1 nM, respectively) [APExBIO]. The compound demonstrates over 180-fold selectivity versus c-Kit and negligible inhibition of VEGFR, EGFR, Lck, and TIE-2 kinases. In vivo, oral administration at 50 mg/kg in rat C6 glioblastoma xenograft models reduces PDGFR-β phosphorylation by more than 50% for 4 hours and inhibits angiogenesis by 70-90% in mouse models. CP-673451 shows efficacy in suppressing tumor growth and reducing microvessel density across multiple xenograft models, including ATRX-deficient glioma cells (Pladevall-Morera et al., 2022). APExBIO supplies CP-673451 for advanced cancer research and PDGFR signaling interrogation.

Biological Rationale

The platelet-derived growth factor receptor (PDGFR) family regulates cell proliferation, survival, and angiogenesis. Dysregulation is implicated in oncogenesis, particularly in glioblastoma and other high-grade gliomas [Cancers 2022]. ATRX mutations, found in various tumor types, are associated with increased sensitivity to PDGFR inhibition, offering a targeted therapeutic strategy for subpopulations such as ATRX-deficient high-grade glioma cells. Effective PDGFR inhibition impairs tumor angiogenesis, slows tumor progression, and complements standard-of-care treatments (e.g., temozolomide in glioblastoma). Thus, precise PDGFR blockade is critical for both mechanistic research and preclinical drug development [internal: CP-673451 in cancer research].

Mechanism of Action of CP-673451

CP-673451 is an ATP-competitive inhibitor that binds the kinase domain of PDGFRα and PDGFRβ, blocking autophosphorylation and downstream signaling. This direct inhibition prevents PDGF-mediated activation of pathways such as PI3K/AKT and MAPK/ERK, reducing cellular proliferation and angiogenic responses. The compound exhibits high selectivity, minimally affecting kinases like VEGFR-1, VEGFR-2, Lck, TIE-2, and EGFR, and shows moderate inhibition of c-Kit (IC₅₀ = 1.1 μM) [APExBIO]. In cellular assays, inhibition of PDGFR-β phosphorylation is observed at IC₅₀ values of 6.4 nM in PAE-β cells, with over 180-fold selectivity against c-Kit in H526 cells.

Evidence & Benchmarks

• CP-673451 inhibits PDGFR-α and PDGFR-β kinase activity with IC₅₀ values of 10 nM and 1 nM, respectively, in biochemical assays (APExBIO).
• In PAE-β cellular assays, CP-673451 blocks PDGFR-β phosphorylation at an IC₅₀ of 6.4 nM, confirming cellular potency (Pladevall-Morera et al., 2022).
• Shows >180-fold selectivity over c-Kit in H526 cell models, minimizing off-target effects (APExBIO).
• Oral dosing at 50 mg/kg in rat C6 glioblastoma xenograft models reduces PDGFR-β phosphorylation by >50% for at least 4 hours and inhibits angiogenesis by 70-90% in mouse sponge models (APExBIO).
• In ATRX-deficient high-grade glioma cells, PDGFR inhibitors including CP-673451 increase toxicity, suggesting therapeutic synergy with temozolomide (Pladevall-Morera et al., 2022).
• Reduces tumor growth and microvessel density in xenograft models (Colo205, LS174T, H460, U87MG), confirming broad in vivo efficacy (APExBIO).

This article extends upon CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research by providing updated evidence on ATRX-deficient glioma models and workflow integration parameters.

For a focused discussion on ATRX-deficient glioma, see CP-673451: Transforming Glioma Research with Selective PD..., which this article refines by adding new mechanistic and selectivity data.

Applications, Limits & Misconceptions

Primary Applications

• Dissecting PDGFR signaling pathways in cancer and angiogenesis models.
• Evaluating anti-angiogenic and anti-proliferative effects in xenograft tumor systems.
• Screening for synergistic effects in ATRX-deficient cancer cell models, especially in combination with temozolomide (Pladevall-Morera et al., 2022).

Common Pitfalls or Misconceptions

• CP-673451 is not effective against tumors lacking PDGFR expression or activation.
• It is not a direct VEGFR or EGFR inhibitor and should not be used as such.
• Water insolubility limits its application in purely aqueous systems without co-solvents (e.g., DMSO).
• Stock solutions in DMSO require storage below -20°C and are not recommended for long-term use in high-throughput screening without stability checks.
• Moderate inhibition of c-Kit (IC₅₀ = 1.1 μM) may confound studies in c-Kit–driven models at high concentrations.

For an in-depth discussion of selectivity and kinase profiling, see CP-673451: Selective PDGFR Inhibitor for Cancer Research ..., which this article updates with detailed workflow integration steps.

Workflow Integration & Parameters

• Solubility: Insoluble in water; dissolve in DMSO (≥20.9 mg/mL) or ethanol (≥2.39 mg/mL with warming/ultrasonication) [APExBIO].
• Storage: Store powder and solutions at -20°C; DMSO stocks stable for several months below -20°C.
• Recommended In Vitro Concentrations: Use sub-micromolar (e.g., 1–100 nM) for PDGFR inhibition assays.
• In Vivo Dosing: Oral administration at 50 mg/kg is effective for phosphorylation and angiogenesis inhibition in rodent models.
• Controls: Always include vehicle (DMSO/ethanol) and, if relevant, a non-PDGFR-driven cell line or model.
• Assay Types: Suitable for Western blot, ELISA, angiogenesis tube formation, and xenograft tumor growth assays.

Consult the CP-673451 product page for detailed protocols and batch-specific data.

Conclusion & Outlook

CP-673451, as provided by APExBIO, is a gold-standard ATP-competitive PDGFRα/β inhibitor with high selectivity and reproducible in vivo efficacy. It is indispensable for dissecting PDGFR signaling, angiogenesis, and tumor growth in preclinical cancer models. As ATRX mutation status emerges as a stratification factor for PDGFR inhibitor efficacy, CP-673451's role in precision oncology research is expected to grow. Future studies are warranted to further refine dosing regimens and explore combination therapies in genetically defined tumor contexts (Pladevall-Morera et al., 2022).